Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
CytomX Therapeutics is a biopharmaceutical company specializing in developing novel, conditionally activated biologics for cancer treatment. Its PROBODY platform enables targeted therapies that activate within the tumor microenvironment, reducing systemic toxicity. The company focuses on antibody-drug conjugates, T-cell engagers, immunotherapies, and mRNA, collaborating with major pharma partners to address unmet oncology needs through innovative, localized biologic drugs.
This description was generated via AI from an annual report. Updated about 1 year ago.